 |
PDBsum entry 1soj
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Crystal structure of human phosphodiesterase 3b: atomic basis for substrate and inhibitor specificity.
|
 |
|
Authors
|
 |
G.Scapin,
S.B.Patel,
C.Chung,
J.P.Varnerin,
S.D.Edmondson,
A.Mastracchio,
E.R.Parmee,
S.B.Singh,
J.W.Becker,
L.H.Van der ploeg,
M.R.Tota.
|
 |
|
Ref.
|
 |
Biochemistry, 2004,
43,
6091-6100.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Phosphodiesterases (PDEs) are enzymes that modulate cyclic nucleotide signaling
and as such are clinical targets for a range of disorders including congestive
heart failure, erectile dysfunction, and inflammation. The PDE3 family comprises
two highly homologous subtypes expressed in different tissues, and inhibitors of
this family have been shown to increase lipolysis in adipocytes. A specific
PDE3B (the lipocyte-localized subtype) inhibitor would be a very useful tool to
evaluate the effects of PDE3 inhibition on lipolysis and metabolic rate and
might become a novel tool for treatment of obesity. We report here the
three-dimensional structures of the catalytic domain of human PDE3B in complex
with a generic PDE inhibitor and a novel PDE3 selective inhibitor. These
structures explain the dual cAMP/cGMP binding capabilities of PDE3, provide the
molecular basis for inhibitor specificity, and can supply a valid platform for
the design of improved compounds.
|
 |
|
|
|
|
 |